Provided by Tiger Fintech (Singapore) Pte. Ltd.

Meiragtx Holdings Plc

7.79
-0.4600-5.58%
Post-market: 7.790.00000.00%19:40 EDT
Volume:1.51M
Turnover:12.20M
Market Cap:608.81M
PE:-5.80
High:8.75
Open:8.56
Low:7.70
Close:8.25
Loading ...

MeiraGTx Holdings Plc - to Retain 30% Ownership in Joint Venture

THOMSON REUTERS
·
13 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Mar

MeiraGTx Holdings PLC expected to post a loss of 56 cents a share - Earnings Preview

Reuters
·
10 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

High Growth Tech Stocks In The United States Spotlighting Three Leaders

Simply Wall St.
·
26 Feb

MeiraGTx Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
24 Feb

MeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release

Dow Jones
·
22 Feb

BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics

Reuters
·
22 Feb

MeiraGTx Shares up 4.3% on Positive Data From Genetic Eye Condition Treatment

THOMSON REUTERS
·
21 Feb

BUZZ-MeiraGTx rises on positive data from genetic eye condition treatment

Reuters
·
21 Feb

MeiraGTx Announces the Lancet Publication of Data Demonstrating the Efficacy of Raav8.hrkp.aipl1 for the Treatment of Leber Congenital Amaurosis 4 (Lca4) Retinal Dystrophy

THOMSON REUTERS
·
21 Feb

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

GlobeNewswire
·
21 Feb

MeiraGTx Holdings plc's (NASDAQ:MGTX) top owners are private equity firms with 25% stake, while 21% is held by institutions

Simply Wall St.
·
30 Jan

MeiraGTx Says FDA Grants Rare Pediatric Disease Designation to Eye Disorder Drug

MT Newswires Live
·
22 Jan

MeiraGTx Receives Rare Pediatric Disease Designation From FDA for Aav8-Rk-Retgc for the Treatment of Patients With Leber Congenital Amaurosis Due to Gucy2d Mutations

THOMSON REUTERS
·
22 Jan

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

GlobeNewswire
·
22 Jan